Policy / Regulatory

NHSA Unveils Updated National Reimbursement Drug List Rules for 2023

CompanyDeals

Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development

CompanyDrug

Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE

Policy / Regulatory

NMPA Proposes Revisions to “Drug Inspection Management Measures”, Seeks Public Feedback

Company

Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy

CompanyDeals

Shanghai’s Huangpu District Launches RMB Fund to Boost Fintech, AI, and Biotech Firms

CompanyDrug

Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study

CompanyDrug

Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing

CompanyDeals

Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round

CompanyDrug

Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China

CompanyDrug

SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment

CompanyDrug

Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis